Spoken Alpha
Vyome Holdings, Inc
Vyome Holdings, Inc. develops clinical-stage therapies for immune-inflammatory and rare diseases, with a lead program (VT-1953) in topical gel form for treating malignant fungating wounds in advanced cancer patients. The company also has ophthalmic and dermatology programs in development, and commercializes antifungal products in India through partnerships.
Vyome Holdings, Inc is a Healthcare company operating in Biotechnology with a $14.1M market cap.
HIND beat consensus EPS by 0.5% in Q2 FY2026, reported Aug 11, 2026.
15 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for HIND.
$ curl https://api.spokenalpha.com/v1/companies/HINDFAQ
Spoken Alpha indexes HIND's earnings call transcripts at https://spokenalpha.com/companies/HIND. Each call links to attributed speakers and parsed analyst Q&A. Vyome Holdings, Inc's own investor relations page is at https://vyometx.com/investors/investor-home.
Vyome Holdings, Inc (HIND) held its most recent earnings call on 2024-11-14, covering fiscal Q3 2024.
Vyome Holdings, Inc (HIND) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-0.10 | $-0.19 | +47.4% | $27.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-25 | $-0.14 | $-0.18 | +20.1% | $31.6K | — | — | EODHD |
| Q4 FY2025 | 2026-03-29 | $-0.21 | $-0.34 | +39.1% | $36.6K | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-3.12 | $-0.11 | -100.0% | $34.6K | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-9.00 | — | — | $1.2M | — | — | EODHD |
| Q1 FY2025 | 2025-04-03 | $-2.47 | $-0.07 | -100.0% | $1.1M | — | — | EODHD |
| Q3 FY2024 | 2024-11-14 | $-310.70 | — | — | $2.3M | — | — | EODHD |
| Q2 FY2024 | 2024-08-14 | $-366.78 | — | — | $2.0M | — | — | EODHD |
| Q1 FY2024 | 2024-05-15 | $-542.24 | — | — | $1.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-5936.62 | — | — | $2.2M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-6235.08 | — | — | $2.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-34.02 | $-10.00 | -100.0% | $2.3M | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.58 | $-32.50 | +98.2% | $2.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.51 | $-0.51 | +1.0% | $2.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-22 | $-0.38 | $-0.34 | -10.6% | $2.4M | — | — | EODHD |
| Q4 FY2021 | 2022-03-27 | $-1.73 | $-0.17 | -100.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-10 | $-0.31 | $-0.15 | -100.0% | $3.7M | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.15 | $-0.22 | +33.6% | $3.5M | — | — | EODHD |
| Q1 FY2021 | 2021-05-11 | $-1.32 | — | — | $3.2M | — | — | EODHD |
| Q4 FY2020 | 2021-03-11 | $-0.51 | $-3.00 | +83.0% | $3.2M | — | — | EODHD |
Source: EODHD. HIND reported actuals as published; sparse fields render as —.